Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells

Seo, Naohiro; Shirakura, Yoshitaka; Tahara, Yoshiro; Momose, Fumiyasu; Harada, Norihiro; Ikeda, Hiroaki; Akiyoshi, Kazunari; Shiku, Hiroshi

doi:10.1038/s41467-018-02865-1

Cited by 173 publications

(142 citation statements)

References 45 publications

Supporting

Mentioning

133

Contrasting

Order By: Relevance

“…Regulatory T cell‐derived EVs can work as suppressors against pathogenic Th1 responses in a miRNA‐dependent manner (Okoye et al, ). Seo et al found that EVs from activated CD8+ T cells were actively involved in interrupting tumor invasion and metastasis by depleting tumor mesenchymal cells (Seo et al, ). A similar performance was also observed for NK cells‐derived exosomes.…”

Section: Nanoparticle‐based Platforms For Cancer Immunotherapymentioning

confidence: 99%

Nanotechnology platforms for cancer immunotherapy

Yang

Zhao

et al. 2019

WIREs Nanomed Nanobiotechnol

104

View full text Add to dashboard Cite

Various cancer therapies have advanced remarkably over the past decade. Unlike the direct therapeutic targeting of tumor cells, cancer immunotherapy is a new strategy that boosts the host's immune system to detect specific cancer cells for efficient elimination. Nanoparticles incorporating immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance antitumor immunity. Such nanoparticle‐based cancer immunotherapies have received considerable attention and have been extensively studied in recent years. This review thus focuses on nanoparticle‐based platforms (especially naturally derived nanoparticles and synthetic nanoparticles) utilized in recent advances; summarizes delivery systems that incorporate various immune‐modulating agents, including peptides and nucleic acids, immune checkpoint inhibitors, and other small immunostimulating agents; and introduces combinational cancer immunotherapy with nanoparticles, especially nanoparticle‐based photo‐immunotherapy and nanoparticle‐based chemo‐immunotherapy. Undoubtedly, the recent studies introduced in this review prove that nanoparticle‐incorporated cancer immunotherapy is a highly promising treatment modality for patients with cancer. Nonetheless further research is needed to solve safety concerns and improve efficacy of nanoplatform‐based cancer immunotherapy for future clinical application. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

show abstract

Section: Nanoparticle‐based Platforms For Cancer Immunotherapymentioning

confidence: 99%

Nanotechnology platforms for cancer immunotherapy

Yang

Zhao

et al. 2019

WIREs Nanomed Nanobiotechnol

104

View full text Add to dashboard Cite

show abstract

“…A few years ago, significant differences had already been reported between the EVs released by tumour cells, which induce immunoregulation, compared to the EVs from immune cells, which induce immunomodulation [65]. A few examples have already been reported in this review [48,50,62]. Improvements developed recently are focused on the treatment of single or various cancers.…”

Section: Diagnosis and Therapymentioning

confidence: 81%

Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases

Meldolesi

2019

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Two types of extracellular vesicles (EVs), exosomes and ectosomes, are generated and released by all cells, including immune cells. The two EVs appear different in many properties: size, mechanism and site of assembly, composition of their membranes and luminal cargoes, sites and processes of release. In functional terms, however, these differences are minor. Moreover, their binding to and effects on target cells appear similar, thus the two types are considered distinct only in a few cases, otherwise they are presented together as EVs. The EV physiology of the various immune cells differs as expected from their differential properties. Some properties, however, are common: EV release, taking place already at rest, is greatly increased upon cell stimulation; extracellular navigation occurs adjacent and at distance from the releasing cells; binding to and uptake by target cells are specific. EVs received from other immune or distinct cells govern many functions in target cells. Immune diseases in which EVs play multiple, often opposite (aggression and protection) effects, are numerous; inflammatory diseases; pathologies of various tissues; and brain diseases, such as multiple sclerosis. EVs also have effects on interactive immune and cancer cells. These effects are often distinct, promoting cytotoxicity or proliferation, the latter together with metastasis and angiogenesis. Diagnoses depend on the identification of EV biomarkers; therapies on various mechanisms such as (1) removal of aggression-inducing EVs; (2) EV manipulations specific for single targets, with insertion of surface peptides or luminal miRNAs; and (3) removal or re-expression of molecules from target cells.

show abstract

“…Surprisingly, CD8 + T cell exosomes exhibit cytotoxicity against tumor stromal cells such as MSCs and CAFs, but not tumor cells. In addition, CD8 + T cell exosome-mediated destruction of mesenchymal stroma associated with the reduction of tumor invasion and metastasis ( Figure 1) [13] .…”

Section: Exosomes From T Cells and Nk Cellsmentioning

confidence: 99%

Exosome-mediated immune regulation and its clinical application

Seo

2018

Trends Immunother

Self Cite

View full text Add to dashboard Cite

Immune system is a precise mechanism for maintenance of homeostasis by lymphocyte-mediated elimination of extracellular and intercellular pathogens, and abnormal cells in cytokine-, chemokine-, antibody-, and cytotoxic granuledependent manners. Extracellular vesicles, e.g. exosomes, released from multivesicular endosome in immune cells have been known to be a part of the immune system. Exosomes released by antigen-presenting cells (APCs)

show abstract

Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells

Cited by 173 publications

References 45 publications

Nanotechnology platforms for cancer immunotherapy

Nanotechnology platforms for cancer immunotherapy

Extracellular vesicles, news about their role in immune cells: physiology, pathology and diseases

Exosome-mediated immune regulation and its clinical application

Contact Info

Product

Resources

About